Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00238121 · OUTCOME

Progression Free Survival

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer · Source last updated 2015-11-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Month
Interval / dispersion
95% Confidence Interval
Time frame
Up to 5 years

What was measured

Defined as the time from the first day of treatment until the date PD(progressive disease) or death is first reported. Patients who died without a reported prior progression was considered to have progressed on the day of their death. Patients who did not progress was censored at the day of their last tumor assessment. According to RECIST, progressive disease(PD) is defined as at least a 20% increase in the sum of the longest diameter of target lesions.

Groups in this outcome

Carcinoma

Patients with advanced uterine carcinoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Carcinosarcoma

Patients with advanced uterine carcinosarcoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Carcinoma38
Carcinosarcoma14

Reported measurements

Source class 1
Values in Month · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Carcinoma3.2Not reported1.94Not reported
Carcinosarcoma1.8Not reported1.43.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.9
        upper Limit
        4
        value
        3.2
      2. group Id
        OG001
        lower Limit
        1.4
        upper Limit
        3.5
        value
        1.8
denoms
  1. counts
    1. group Id
      OG000
      value
      38
    2. group Id
      OG001
      value
      14
    units
    Participants
description
Defined as the time from the first day of treatment until the date PD(progressive disease) or death is first reported. Patients who died without a reported prior progression was considered to have progressed on the day of their death. Patients who did not progress was censored at the day of their last tumor assessment. According to RECIST, progressive disease(PD) is defined as at least a 20% increase in the sum of the longest diameter of target lesions.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients with advanced uterine carcinoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Carcinoma
  2. description
    Patients with advanced uterine carcinosarcoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG001
    title
    Carcinosarcoma
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 5 years
title
Progression Free Survival
type
SECONDARY
unit Of Measure
Month

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice